List of Excipients in Branded Drug ROWASA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	CARBOMER HOMOPOLYMER TYPE B
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	EDETATE DISODIUM
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	POTASSIUM ACETATE
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	POTASSIUM METABISULFITE
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	SODIUM BENZOATE
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	WATER
Viatris Specialty LLC	ROWASA	mesalamine	0037-0066	XANTHAN GUM

ROWASA Excipient Strategy and Commercial Opportunities in Mesalamine Rectal Suspension

Last updated: August 19, 2026

ROWASA is a mesalamine 4 g/60 mL rectal suspension used for active mild-to-moderate ulcerative proctitis. Its commercial value is tied less to the active ingredient, which is widely available, than to local delivery, suspension stability, preservative performance, tolerability, and patient adherence. The principal excipient opportunity is to improve the enema platform without compromising dose uniformity, retention, microbial control, or regulatory comparability.

What is ROWASA and how does its formulation work?

ROWASA is a rectally administered aqueous suspension containing 4 g of mesalamine in a 60 mL unit dose. The product is administered at bedtime and is intended to be retained for approximately eight hours. Mesalamine acts locally in the colonic mucosa and has limited systemic exposure compared with oral dosage forms.[1]

Product attribute	ROWASA profile
Active ingredient	Mesalamine
Dosage form	Rectal suspension enema
Strength	4 g per 60 mL
Route	Rectal
Indication	Active mild-to-moderate ulcerative proctitis
FDA pathway	New drug application
Originator company	Salix Pharmaceuticals, a Bausch Health company
Administration	Single-use rectal unit dose
Key delivery requirement	Local deposition and overnight retention

The formulation uses excipients that control viscosity, preserve the aqueous product, support physical suspension, and manage oxidation or microbial risk.

Which excipients are used in ROWASA?

The ROWASA labeling identifies benzoic acid, carbomer 934P, potassium metabisulfite, sodium benzoate, xanthan gum, and water as inactive ingredients.[1]

Excipient	Likely formulation role	Commercial relevance
Carbomer 934P	Rheology modifier and suspending agent	Controls viscosity, sedimentation, and dose uniformity
Xanthan gum	Suspending and viscosity-enhancing agent	Supports physical stability and mucosal residence
Sodium benzoate	Preservative	Supports antimicrobial protection in the aqueous system
Benzoic acid	Preservative and pH-related component	Works with sodium benzoate as a preservative system
Potassium metabisulfite	Antioxidant or reducing agent	May limit oxidative degradation
Purified water	Vehicle	Determines dispersion, viscosity, and microbial-control requirements

The excipient system has a direct effect on patient experience. Excessive viscosity can complicate administration and retention. Insufficient viscosity can increase sedimentation, create dose nonuniformity, and reduce mucosal contact. The commercial challenge is to balance these variables while maintaining a stable, homogeneous suspension through the labeled shelf life.

What excipient strategies could improve ROWASA?

The strongest opportunities are sulfite reduction, preservative redesign, lower-volume delivery, improved suspendability, and alternative local-delivery formats.

Can a sulfite-free ROWASA formulation create commercial value?

Potassium metabisulfite is a potential differentiator because sulfite sensitivity is clinically relevant for a subset of patients, particularly some individuals with asthma. Removing or replacing the sulfite could support a cleaner label and reduce a tolerability concern.

A sulfite-free formulation would require a broader stability and microbiology program. The developer would need to demonstrate:

• Comparable mesalamine chemical stability
• Comparable impurity profile
• Adequate microbial control
• Acceptable container-closure integrity
• No clinically meaningful change in rectal tolerability
• Preserved suspension uniformity during storage and use

Potential alternatives include oxygen-control packaging, lower-oxygen headspace, chelating systems, pH optimization, or other antioxidant approaches. Each option creates regulatory and intellectual-property considerations. A formulation with a novel antioxidant system could support a 505(b)(2) strategy, but it could also face excipient safety and compatibility questions.

What is the opportunity for preservative-free mesalamine enemas?

A preservative-free product could appeal to patients with rectal irritation, sensitivity to benzoates, or preference for simplified formulations. The main technical obstacle is the aqueous, single-use presentation. A preservative-free design would need to rely on unit-dose packaging, validated aseptic manufacture, terminal sterilization where compatible, or a tightly controlled microbial specification.

The commercial opportunity is strongest if the product can show one or more of the following:

1. Reduced burning or irritation.
2. Better use in patients with excipient sensitivities.
3. Improved adherence during active disease.
4. Differentiation from standard generic mesalamine enemas.
5. Premium positioning in specialty pharmacy.

The cost burden would likely rise because aseptic processing and microbiological controls are more demanding than conventional preserved liquid manufacture.

Can viscosity and suspension performance be improved?

Carbomer and xanthan gum provide a platform for optimizing rheology. A redesigned formulation could target:

• Faster redispersion before use
• Lower sedimentation during storage
• Lower administration force
• More consistent delivered dose
• Improved mucosal coating
• Better retention after administration

The critical tradeoff is that a more viscous suspension may improve residence time but reduce usability. A product that requires vigorous shaking, has a high extrusion force, or causes leakage can lose adherence advantages despite stronger technical performance.

A commercially attractive formulation would use rheological testing under conditions that reflect actual use, including storage, shaking, administration through the applicator, and exposure to body temperature.

What formulations could compete with ROWASA?

The principal competing formats are rectal suppositories, foams, gels, and oral mesalamine products. Each dosage form addresses a different disease distribution and patient preference.

Formulation	Main commercial advantage	Main limitation
ROWASA-type enema	Delivers a high mesalamine dose to the rectum and distal colon	Administration burden and retention difficulty
Mesalamine suppository	Convenient and compact	More limited distribution, mainly rectal
Rectal foam	Lower perceived administration burden and improved spread	Device and propellant complexity
Rectal gel	Potentially good mucosal coverage	Stability, preservative, and applicator issues
Oral mesalamine	Convenient systemic delivery to the colon	Higher systemic exposure and dependence on release technology
Combination oral and rectal therapy	Addresses broader colonic disease	Higher treatment burden and cost

Is a foam or low-volume product a stronger commercial opportunity?

A low-volume foam or gel could compete effectively on convenience. Many patients discontinue rectal therapy because of discomfort, leakage, or difficulty retaining a liquid enema. Reducing the volume while maintaining mucosal coverage could improve adherence.

The development burden is substantial. A foam or gel must establish:

• Consistent dose delivery from the device
• Product performance across canister life
• Applicator compatibility
• Distribution across the target anatomy
• Local safety
• Stability of the active ingredient and excipients
• Acceptable device-human factors performance

A lower-volume product may receive a stronger commercial premium than an excipient-only reformulation because the patient benefit is easier to communicate.

What regulatory pathway applies to a ROWASA generic?

A conventional generic mesalamine rectal suspension would generally proceed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA standards.[2]

For a complex suspension, the principal development issues include:

• Same active ingredient, strength, route, and dosage form
• Comparable inactive-ingredient controls
• Particle-size and dispersion characterization
• Suspension uniformity
• Delivered-dose reproducibility
• In-use stability
• Microbial limits and preservative effectiveness
• Device and applicator performance
• Comparative bioequivalence evidence

A product with a materially different excipient system, new delivery device, altered indication, or new clinical performance claim may require a 505(b)(2) application rather than a standard ANDA. That route can support differentiated products but generally requires more clinical, pharmacology, or bridging evidence.

What is the Orange Book status of ROWASA?

ROWASA is associated with an FDA-approved NDA, and FDA’s Orange Book is the controlling source for listed patents, exclusivity, therapeutic-equivalence codes, and approved reference-product information.[3]

Orange Book issue	Commercial implication
Reference listed drug status	Establishes the product used for generic comparison
Listed patents	Can require certification or expiration analysis
Paragraph IV certification	May trigger patent litigation and a potential 30-month stay
Therapeutic-equivalence code	Affects substitution and pharmacy adoption
Exclusivity status	Determines regulatory timing for competing applications

The patent position should be analyzed at the NDA and product level rather than inferred from the age of mesalamine. The active ingredient is mature, but formulation, manufacturing, device, and method-of-use rights may have different terms and legal status.

What patents protect ROWASA and its excipient technology?

The commercially relevant patent categories are:

Formulation patents

These may cover:

• Specific suspending-agent combinations
• Preservative systems
• Antioxidant systems
• pH ranges
• Viscosity windows
• Particle-size distributions
• Sedimentation-control parameters
• Unit-dose packaging

Formulation claims are potentially valuable where the excipient combination produces measurable stability, dose-uniformity, or retention benefits. Their strength depends on claim scope, prior art, written-description support, and whether the claimed ranges produce unexpected results.

Method-of-use patents

Method patents may address treatment of ulcerative proctitis, distal ulcerative colitis, dosing schedules, or combination use with oral mesalamine. Their practical value depends on whether the indication is carved out of a generic label and whether the patented method is commercially material to prescribing.

Manufacturing and packaging patents

Manufacturing claims may cover suspension preparation, deaeration, filling, container closure, or applicator configuration. These rights can raise switching costs but are less effective if competitors can achieve equivalent product performance through a different process.

When does ROWASA lose exclusivity and what generic entry risks exist?

Mesalamine is a mature small molecule, so biosimilar risk does not apply. The competitive threat is from generic ANDA applicants and reformulated products.

Generic entry risk depends on four factors:

1. Whether enforceable Orange Book patents remain listed.
2. Whether applicants file paragraph III or paragraph IV certifications.
3. Whether litigation produces a stay, settlement, or launch restriction.
4. Whether the generic achieves favorable substitution and payer coverage.

A paragraph IV filing can lead to patent litigation within 45 days of notice to the patent holder. A timely suit can trigger a statutory 30-month stay of approval, subject to statutory exceptions and court decisions.[2]

The key launch scenarios are:

Scenario	Likely market effect
No blocking patents	Rapid price erosion after approval
Paragraph IV litigation with stay	Delayed generic approval or launch
Settlement with licensed entry	Date-certain competitive entry
Non-infringement or invalidity finding	Earlier generic launch
Authorized generic launch	Lower-price competition controlled by the brand owner
Differentiated 505(b)(2) product	Premium competition based on convenience or tolerability

Which companies are challenging ROWASA?

Generic mesalamine products have been developed by multiple manufacturers over time, but current applicant and litigation status must be determined from FDA approval records, Orange Book entries, ANDA litigation dockets, and applicable court filings. The relevant competitive set includes manufacturers of mesalamine rectal suspension and developers of alternative rectal formulations.

Because mesalamine rectal suspension is a complex liquid product, competition is constrained by formulation and manufacturing execution rather than active-ingredient access alone. The most credible competitors are those with established sterile or controlled liquid manufacturing, rectal delivery-device capabilities, and specialty-pharmacy distribution.

How strong is the ROWASA patent estate?

The underlying active-ingredient position is weak because mesalamine is an established molecule. The potential strength lies in formulation-specific and delivery-specific rights.

Patent category	Strategic strength
Mesalamine molecule	Low
Basic rectal use	Low to moderate, depending on claim status
Suspension excipient combination	Moderate if narrowly supported by data
Low-volume foam or gel	Potentially strong if clinically differentiated
Applicator or packaging	Moderate, with design-around risk
Manufacturing process	Moderate, depending on process dependence
Method-of-use claim	Variable and often vulnerable to label carve-outs

A strong modern estate would combine composition claims, process claims, device claims, and clinically meaningful method-of-use claims. A single narrow excipient claim is less durable because competitors can substitute polymers, preservatives, antioxidants, or packaging components.

What licensing deals could support ROWASA reformulation?

Licensing opportunities could arise around:

• Novel rectal foam or gel platforms
• Mucoadhesive polymers
• Sulfite-free antioxidant systems
• Preservative-free aqueous packaging
• Applicator technology
• Microbiome-compatible excipients
• Manufacturing processes for high-solids suspensions

The most valuable licensing structure would link upfront rights to development milestones, regulatory approval, and commercial sales. A formulation license should define ownership of improvements, field-of-use restrictions, geographic rights, supply obligations, and patent-prosecution control.

What is the revenue exposure for ROWASA?

Public financial reporting generally does not isolate ROWASA revenue from broader Salix or Bausch pharmaceutical sales. Revenue exposure should therefore be assessed through product-level prescription volume, net price, payer mix, generic share, and specialty-pharmacy channel data rather than corporate segment disclosure alone.

The main revenue risks are generic price erosion, substitution, loss of formulary preference, and declining use of enemas relative to foam or oral products. The main growth opportunities are premium differentiated delivery, adherence improvement, and lifecycle expansion into broader distal ulcerative colitis treatment.

Key Takeaways

• ROWASA is a 4 g/60 mL mesalamine rectal suspension for ulcerative proctitis.
• Its commercial differentiation depends on excipient performance and rectal delivery, not molecule exclusivity.
• The current excipient platform uses carbomer 934P, xanthan gum, benzoic acid, sodium benzoate, potassium metabisulfite, and water.
• Sulfite-free, preservative-free, lower-volume, foam, and gel formulations offer the clearest lifecycle opportunities.
• Generic competition is governed by Orange Book patents, ANDA requirements, paragraph IV certifications, and therapeutic-equivalence outcomes.
• Biosimilars are irrelevant because mesalamine is a small molecule.
• Formulation and device patents can provide value, but narrow excipient claims face design-around and obviousness risks.
• A differentiated 505(b)(2) product may command more commercial value than a conventional generic suspension.

FAQs About ROWASA Excipient Strategy

What is the most important excipient in ROWASA?

Carbomer 934P and xanthan gum are central to suspension stability, viscosity, redispersion, and mucosal residence. Their concentrations and interaction with the preservative system can materially affect product performance.

Could a preservative-free ROWASA generic be approved?

Yes, but a preservative-free product would require an appropriate regulatory pathway and evidence for microbiological quality, stability, packaging integrity, and product performance. It may not qualify as a conventional equivalent if the formulation differences are material.

Does ROWASA have biosimilar competition?

No. Mesalamine is a chemically synthesized small molecule. Competition proceeds through generic drug and reformulation pathways rather than the biosimilar pathway.

Which excipient changes could support a premium product?

A sulfite-free antioxidant system, lower-irritancy preservative system, reduced-volume vehicle, improved mucoadhesive polymer blend, or patient-friendly applicator could support premium positioning if linked to measurable tolerability or adherence benefits.

What is the largest commercial threat to ROWASA?

The largest threat is a combination of generic mesalamine rectal suspension, lower-volume rectal foams, and oral mesalamine products that reduce the perceived burden of rectal administration.

References

1. U.S. Food and Drug Administration. (n.d.). ROWASA (mesalamine) rectal suspension prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and therapeutic equivalence evaluations.